Jazz Pharmaceuticals director sells 5,500 JAZZ shares at $180.86

Jazz Pharmaceuticals plc (JAZZ) director Rick E. Winningham reported a sale of company stock.

Rhea-AI Filing Summary

Jazz Pharmaceuticals plc (JAZZ) director Rick E. Winningham reported a sale of company stock. On 11/18/2025, he sold 5,500 ordinary shares of Jazz Pharmaceuticals at a price of $180.8597 per share. After this transaction, he beneficially owned 8,893 ordinary shares, held directly. This filing is a routine disclosure of insider trading activity required under securities regulations.

Insider Trade Summary

Net Seller: 5,500 shares

Net Sell 1 txn

Insider Winningham Rick E

Role Director

Sold 5,500 shs ($995K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	5,500	$180.8597	$995K

Holdings After Transaction: Ordinary Shares — 8,893 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jazz Pharmaceuticals (JAZZ) report in this Form 4?

A director, Rick E. Winningham, reported selling 5,500 ordinary shares of Jazz Pharmaceuticals on 11/18/2025.

At what price were the Jazz Pharmaceuticals (JAZZ) shares sold?

The 5,500 ordinary shares were sold at a price of $180.8597 per share.

How many Jazz Pharmaceuticals shares does the director own after the sale?

Following the reported transaction, the director beneficially owned 8,893 ordinary shares of Jazz Pharmaceuticals, held directly.

What is the relationship of the reporting person to Jazz Pharmaceuticals (JAZZ)?

The reporting person, Rick E. Winningham, is listed as a Director of Jazz Pharmaceuticals.

Is this Jazz Pharmaceuticals (JAZZ) filing made by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person.

What type of security was involved in the Jazz Pharmaceuticals (JAZZ) insider transaction?

The transaction involved ordinary shares of Jazz Pharmaceuticals plc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 05:54 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Winningham Rick E

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	11/18/2025		S		5,500	D	$180.8597	8,893	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/Adam Guttmann, as attorney in fact For: Rick E Winningham	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.